Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 13:41
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:13
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:13
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:12
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:12
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:12
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:06
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:06
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:03
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 12:02
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 11:59
Proceedings from the 9th Annual Winter Lung Cancer Conference
Submitted by mphilemon@resea... on Fri, 05/04/2012 - 11:50
Excerpts from Rounds with the Investigators Multiple Myeloma and Lung Cancer Meetings, 2012
Submitted by jwr@option4.com on Mon, 04/30/2012 - 14:39
Excerpts from 2012 Rounds with the Investigators Multiple Myeloma, Lung Cancer and Breast Cancer Meetings
Rounds with Investigators 2012 | Multiple Myeloma — Link #7
Submitted by jwr@option4.com on Mon, 04/30/2012 - 13:26
Rounds with the Investigators 2012 | Multiple Myeloma
Rounds with Investigators 2012 | Multiple Myeloma — Link #6
Submitted by jwr@option4.com on Mon, 04/30/2012 - 13:26
Rounds with the Investigators 2012 | Multiple Myeloma
QUESTION: What is the best risk stratification test: cytogenetics, FISH, MyPRS™ GEP70, other GEP tests or “other”?
DR RAFAEL FONSECA: The question is a very pertinent one because I think more and more people have moved away from conventional or classic cytogenetics and I think there’s a good reason for that. Sure enough, if they’re abnormal, you know that the patient has very high-risk disease. But the yield for abnormalities, this is about 8 to 9% of cases that you get informative metaphases. So it’s, for the most part, it’s just wasting money, the other 90% of patients.